INDSWFTLTD vs NOVARTIND: Stock Comparison
Ind-Swift Limited shows a higher net margin, while Novartis India Limited shows a higher dividend yield, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
INDSWFTLTD leads 4; NOVARTIND leads 5 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | INDSWFTLTD | NOVARTIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | INDSWFTLTD | NOVARTIND |
|---|---|---|
| Live Price | ₹15.76 | ₹1,486.3 |
| Day Change | 6.13% | -1.06% |
| Volume | 6.45 L | 6,845 |
| 52-Week High | ₹17.82 | ₹1,780 |
| 52-Week Low | ₹15.15 | ₹950 |
| Distance from 52W High | -11.56% | -16.5% |
Valuation
| Metric | INDSWFTLTD | NOVARTIND |
|---|---|---|
| Market Cap | ₹0 Cr | ₹3,664 Cr |
| P/E Ratio | — | 37.65x |
| P/B Ratio | — | 4.5x |
| EPS | ₹0 | ₹37.76 |
| Book Value | ₹-122 | ₹331.34 |
| Dividend Yield | 0% | 1.7% |
Growth
| Metric | INDSWFTLTD | NOVARTIND |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 8% |
| EPS Growth (TTM YoY) | 0% | -13.8% |
| Qtr Sales Growth | 0% | 7.95% |
| Qtr Profit Growth | 0% | -13.8% |
Profitability & Leverage
| Metric | INDSWFTLTD | NOVARTIND |
|---|---|---|
| ROE | — | 11.6% |
| ROCE | 13.4% | 16.2% |
| Net Margin | 55.01% | 26.3% |
| Operating Margin | 63.48% | 26.6% |
| Debt to Equity | — | 0x |
Shareholding
As of Jun 2025 • change vs previous quarter| Metric | INDSWFTLTD | NOVARTIND |
|---|---|---|
| Promoter Holding | 55.58% | 0% |
| FII Holding | 0% | 0.16%▼ 0.01 pp |
| DII Holding | 0% | 1.36%▲ 0.83 pp |
| Public Holding | 44.42% | 27.8%▼ 0.81 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Ind-Swift Limited and Novartis India Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.